JP2019511460A5 - - Google Patents

Download PDF

Info

Publication number
JP2019511460A5
JP2019511460A5 JP2018540011A JP2018540011A JP2019511460A5 JP 2019511460 A5 JP2019511460 A5 JP 2019511460A5 JP 2018540011 A JP2018540011 A JP 2018540011A JP 2018540011 A JP2018540011 A JP 2018540011A JP 2019511460 A5 JP2019511460 A5 JP 2019511460A5
Authority
JP
Japan
Prior art keywords
compound
cancer
group
tumor
heterocycloalkylalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018540011A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511460A (ja
JP7030701B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2016/015817 external-priority patent/WO2016123571A1/en
Application filed filed Critical
Priority claimed from PCT/US2017/015608 external-priority patent/WO2017132661A2/en
Publication of JP2019511460A publication Critical patent/JP2019511460A/ja
Publication of JP2019511460A5 publication Critical patent/JP2019511460A5/ja
Priority to JP2021200772A priority Critical patent/JP2022046528A/ja
Application granted granted Critical
Publication of JP7030701B2 publication Critical patent/JP7030701B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018540011A 2016-01-29 2017-01-30 イミプリドンによるgタンパク質共役受容体(gpcr)の調節 Active JP7030701B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021200772A JP2022046528A (ja) 2016-01-29 2021-12-10 イミプリドンによるgタンパク質共役受容体(gpcr)の調節

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
USPCT/US2016/015817 2016-01-29
PCT/US2016/015817 WO2016123571A1 (en) 2015-01-30 2016-01-29 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy
US201662308325P 2016-03-15 2016-03-15
US62/308,325 2016-03-15
US201662425403P 2016-11-22 2016-11-22
US62/425,403 2016-11-22
PCT/US2017/015608 WO2017132661A2 (en) 2016-01-29 2017-01-30 G protein-coupled receptor (gpcr) modulation by imipridones

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021200772A Division JP2022046528A (ja) 2016-01-29 2021-12-10 イミプリドンによるgタンパク質共役受容体(gpcr)の調節

Publications (3)

Publication Number Publication Date
JP2019511460A JP2019511460A (ja) 2019-04-25
JP2019511460A5 true JP2019511460A5 (OSRAM) 2020-03-05
JP7030701B2 JP7030701B2 (ja) 2022-03-07

Family

ID=59398848

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018540011A Active JP7030701B2 (ja) 2016-01-29 2017-01-30 イミプリドンによるgタンパク質共役受容体(gpcr)の調節
JP2021200772A Pending JP2022046528A (ja) 2016-01-29 2021-12-10 イミプリドンによるgタンパク質共役受容体(gpcr)の調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021200772A Pending JP2022046528A (ja) 2016-01-29 2021-12-10 イミプリドンによるgタンパク質共役受容体(gpcr)の調節

Country Status (25)

Country Link
US (2) US11116771B2 (OSRAM)
EP (2) EP4524567A3 (OSRAM)
JP (2) JP7030701B2 (OSRAM)
KR (2) KR102801670B1 (OSRAM)
CN (2) CN115844895B (OSRAM)
AU (2) AU2017211423B2 (OSRAM)
BR (1) BR112018015590A2 (OSRAM)
CA (1) CA3013044A1 (OSRAM)
DK (1) DK3408298T3 (OSRAM)
ES (1) ES3012491T3 (OSRAM)
FI (1) FI3408298T3 (OSRAM)
HR (1) HRP20250207T1 (OSRAM)
HU (1) HUE070208T2 (OSRAM)
IL (3) IL286923B2 (OSRAM)
LT (1) LT3408298T (OSRAM)
MA (1) MA43879B1 (OSRAM)
MX (2) MX2018009227A (OSRAM)
NZ (1) NZ745425A (OSRAM)
PL (1) PL3408298T3 (OSRAM)
PT (1) PT3408298T (OSRAM)
RS (1) RS66519B1 (OSRAM)
SG (2) SG11201806401YA (OSRAM)
SI (1) SI3408298T1 (OSRAM)
SM (1) SMT202500086T1 (OSRAM)
WO (1) WO2017132661A2 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018015590A2 (pt) * 2016-01-29 2019-10-01 Oncoceutics Inc modulação de receptor acoplado à proteína g (gpcr) por imipridonas
US10172862B2 (en) * 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
US20210125683A1 (en) * 2017-09-15 2021-04-29 The Regents Of The University Of California Detecting somatic single nucleotide variants from cell-free nucleic acid with application to minimal residual disease monitoring
US11674963B2 (en) 2017-09-27 2023-06-13 The Regents Of The University Of California GPCRs in cancer-associated fibroblasts
CA3089864A1 (en) 2018-01-31 2019-08-08 Mayo Foundation For Medical Education And Research Methods of treating fibrotic pathologies
JP2021521141A (ja) * 2018-04-09 2021-08-26 オージェネシス インコーポレイテッド バイオキソーム粒子、レドキソーム、それらの作製方法、及びそれらを含む組成物
CN109157656B (zh) * 2018-10-15 2021-08-27 重庆医科大学附属永川医院 一种双靶标肿瘤疫苗及其制备方法和应用
US20220143024A1 (en) * 2019-02-22 2022-05-12 Board Of Regents, The University Of Texas System Methods of using imipridones
EP4378532B1 (en) 2019-07-30 2025-11-12 Mayo Foundation for Medical Education and Research Compounds and methods for treating fibrotic pathologies
KR102403686B1 (ko) 2020-05-15 2022-05-31 뉴로핏 주식회사 뇌자극 위치 제공장치 및 방법
EP4192467A1 (en) 2020-08-06 2023-06-14 Eötvös Loránd Tudományegyetem Synthesis of novel imipridone derivatives and their evaluation for their anticancer activity
CN112402439A (zh) * 2020-11-18 2021-02-26 西安组织工程与再生医学研究所 miR-325核酸类似物在制备改善肝胶原沉积相关产品中的应用
US11648248B1 (en) 2022-01-12 2023-05-16 King Abdulaziz University Potent antimicrobial compounds with a pyridazine nucleus
WO2024031030A2 (en) * 2022-08-03 2024-02-08 Shi Xiandong Quantitative method of determining a mental status based on drd1 and/or drd5, and its application thereof
CN115531378B (zh) * 2022-10-19 2023-10-13 中国医学科学院医药生物技术研究所 Pht427作为ndm-1与kpc-2双重抑制剂的应用
WO2024157207A1 (en) * 2023-01-25 2024-08-02 Gpcr Therapeutics, Inc. Gpcr inhibitors and uses thereof
WO2024218275A1 (en) * 2023-04-20 2024-10-24 Institut Gustave Roussy Liquid and solid compositions of imipridone derivatives
CN116731136B (zh) * 2023-08-04 2023-12-05 齐鲁工业大学(山东省科学院) H3k23a组蛋白点突变在提高酿酒酵母乙酸耐受性及木糖发酵性能中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2150062A1 (de) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004082570A2 (en) * 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2)
US20070026402A1 (en) * 2003-07-08 2007-02-01 Noble Ernest P Genetic marker of response to atypical antipsychotics and antidepressants methods for use thereof
US8088895B2 (en) 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
CA2699912A1 (en) 2007-09-19 2009-03-26 Oncofluor, Inc. Method for imaging and treating organs and tissues
CA2865819A1 (en) 2011-02-28 2013-09-07 Mcmaster University Treatment of cancer with dopamine receptor antagonists
PT2701708T (pt) * 2011-04-29 2020-05-08 Penn State Res Found Indução de gene trail de moléculas pequenas através de células tumorais e normais como uma terapia anticancro
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
RS59013B1 (sr) 2013-03-13 2019-08-30 Oncoceutics Inc 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za upotrebu u lečenju kancera
HUE043291T2 (hu) * 2013-11-15 2019-08-28 Oncoceutics Inc 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a] pirido[3,4-e]pirimidin-5(lH)-on, sói és alkalmazási eljárások
US10239877B2 (en) * 2014-03-31 2019-03-26 The Scripps Research Institute Pharmacophore for trail induction
SMT202500087T1 (it) * 2015-01-30 2025-03-12 Oncoceutics Inc Derivati di 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, loro sali e loro uso in terapia
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
BR112018015590A2 (pt) * 2016-01-29 2019-10-01 Oncoceutics Inc modulação de receptor acoplado à proteína g (gpcr) por imipridonas
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas

Similar Documents

Publication Publication Date Title
JP2019511460A5 (OSRAM)
JP2012508252A5 (OSRAM)
JP2020502092A5 (OSRAM)
JP2019524883A5 (OSRAM)
JP2019537570A5 (OSRAM)
JP2019514884A5 (OSRAM)
JP2018522033A5 (OSRAM)
WO2016105528A3 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP2016532715A5 (OSRAM)
JP2014526435A5 (OSRAM)
JP2017509689A5 (OSRAM)
FI3406609T3 (fi) Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina
JP2016517857A5 (OSRAM)
JP2018536653A5 (OSRAM)
AR096371A1 (es) 2-fenilimidazo[1,2-a]pirimidinas
JP2015501783A5 (OSRAM)
JP2012530779A5 (OSRAM)
RU2016134751A (ru) Соединения
JP2019525939A5 (OSRAM)
JP2015508092A5 (OSRAM)
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
JP2012518634A5 (OSRAM)
JP2015502367A5 (OSRAM)
EP2416795A4 (en) COGNITIVE DECLINE INHIBITORS
JP2019535825A5 (OSRAM)